Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer
2015-005556-10Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer and esophagogastric junction cancer comparing Adjuvant nivolumab with Adjuvant placebo (2 arms). Primary endpoint: Disease-free survival. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2015-005556-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005556-10.